All News

Secure Access Solutions, a spin-off from the University of Warwick, has developed a new kind of magnifying lens to help the visually impaired type their pin codes into card readers in shops. It is seeking licensees and investors.

With global revenues of $110 billion last year, and an aging population, the nascent "neurotechnology" market appears poised for huge growth.

Frost & Sullivan puts some flesh on the bones of the idea that nanotechnology can be a profitable tool in drug development.

The UK government has created two new Enterprise Capital Funds (ECF) under its £40 million scheme to aid high tech businesses caught in the equity gap.

The lack of funding from the private sector is still holding back the development of the European biotech sector vis a vis the US despite a similar number of companies in each.

Researchers at four European universities are collaborating to develop software that will help encourage the take-up of so called pervasive computing.

Nanomedicine can be more than a case of adding a trendy label to traditional approaches to pharmaceuticals.

Last week's Innovate2006 conference in Zaragoza included a pre-conference tour of the region with an interesting visit of Endesa and one of the largest Spanish windmill farms, located just a few miles north off Zaragoza.

Yet another consultation is under way into the safety of nanotechnology. This time you have an opportunity to give your views on "the use of nanotechnologies in relation to food".

Intellectual property battles are not always settled in the marketplace. Epic, life-and-death struggles often take place in the judicial arena.

A team of Danish researchers has devised a method for developing faster silicon computer chips, and is now seeking investment to develop the technique.

Swiss researchers have devised a way to make X-ray imaging much more sensitive – and capable of being incorporated into current medical imaging equipment.

OncoMethylome Sciences is planning to raise funds via an IPO. Its diagnostics can detect early-stage cancer and predict the response to particular cancer drugs.

The controversial proposal for a new European Institute of Technology hit more political turbulence, as the EU’s research commissioner questioned whether it should receive preferential funding.

Without access to easy to use analysis tools, patents are becoming an expensive hindrance to many small companies, says Mick McLean, Head of Economics and Public Policy at Scientific Generics.